Latest Reimbursement News

Page 8 of 50
JPMorgan Emerging Markets Research Enhanced Index Equity Fund nearly trebled its net assets in 2026 after attracting $48.5 million of applications and recording a $4.6 million profit. The growth came with a sharp increase in exposure to one underlying emerging markets ETF.
Claire Turing
Claire Turing
14 Sept 2026
JPMorgan Global Research Enhanced Index Equity Trust reported a sharp rise in operating profit and net assets for the year ended 30 June 2026, powered largely by fair value gains across its global portfolio. Distributions also increased substantially, particularly for hedged classes, although the report does not show whether the Fund outperformed its benchmark.
Victor Sage
Victor Sage
14 Sept 2026
Pacific Edge is positioning Cxbladder for a Medicare-led recovery, but the company remains loss-making with NZ$7.8 million in net cash after a difficult FY26. The investment case now turns on final US coverage, test volumes and whether the enlarged balance sheet can carry the business to scale.
Ada Torres
Ada Torres
14 Sept 2026
Telix’s Pixclara has become the first FDA-approved FET-PET imaging drug for glioma, opening a new US diagnostic pathway for adults and children. The approval is commercially significant, but pricing, reimbursement and launch timing remain undisclosed.
Victor Sage
Victor Sage
14 Sept 2026
Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.
Ada Torres
Ada Torres
10 Sept 2026
Bannerman Energy has completed a fully underwritten A$124 million institutional placement, giving the Etango uranium project a funding pathway through construction and ramp-up. The company now turns to a targeted Q4 2026 Final Investment Decision, while a further non-underwritten shareholder offer could raise up to A$10 million.
Maxwell Dee
Maxwell Dee
10 Sept 2026
St Barbara will sell its remaining New Simberi interest and Tabar Islands exploration exposure to Lingbao for A$453 million in cash, while retaining royalties over future production. The deal could leave the gold developer with about A$880 million in cash, but completion still depends on regulatory and potentially shareholder approvals.
Maxwell Dee
Maxwell Dee
10 Sept 2026
Bannerman Energy has launched a fully underwritten A$124 million placement that it expects will fund its share of the Etango uranium project through construction and ramp-up. The raising follows confirmation that CNOL’s strategic investment and joint venture conditions have been satisfied or waived.
Maxwell Dee
Maxwell Dee
9 Sept 2026
Viridis Mining and Minerals has secured approval for a R$77.5 million BNDES financing facility, reducing the estimated senior debt still required for its Colossus rare earth project to about US$280 million. The 16-year facility carries an indicative current cost of approximately 4.8% and supports the project’s Brazilian processing and research infrastructure.
Maxwell Dee
Maxwell Dee
9 Sept 2026
FBR has fully underwritten its A$2.5 million share purchase plan, removing the immediate risk of an unfunded shortfall but adding cash fees and potential option dilution. Alpine Capital can also terminate the arrangement in several circumstances, including a 10% fall in the S&P/ASX 200 Index.
Sophie Babbage
Sophie Babbage
8 Sept 2026
Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.
Ada Torres
Ada Torres
8 Sept 2026
Albion Resources has locked in a three-month exclusive option to acquire four exploration licences adjacent to its Gidgee Gold Project, adding about 27 square kilometres of highly prospective ground near known high-grade gold zones and polymetallic targets.
Maxwell Dee
Maxwell Dee
4 Sept 2026

Browse the archive

Full archive